Nam H Dang, M.D., Ph.D.
(352) 265-0725
Current patients: Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody. Secondary Gamma-Delta T-Cell Lymphoma Not Otherwise Specified (NOS) From Chronic Immunosuppression. Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Diffuse Large B-Cell Lymphoma Presenting as an Unusual Paraneoplastic Neurologic Syndrome Affecting the Central and Peripheral Nervous Systems. CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions. A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer. Successful Surgical Removal of the Largest Known Spleen. Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience. Intravascular Large B-Cell Lymphoma Presenting as Acute Axonal Polyneuropathy: A Case Report and Literature Review. Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer. Bilateral pseudohypopyon causing white eyes in a patient with lymphoma. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. DPP8 is a novel therapeutic target for multiple myeloma. Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. Biological Effects of IL-26 on T Cell-Mediated Skin Inflammation, Including Psoriasis. A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers. Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. Role of IL-26+CD26+CD4 T Cells in Pulmonary Chronic Graft-Versus-Host Disease and Treatment with Caveolin-1-Ig Fc Conjugate. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer. Low Grade Lymphoma Mimicking Metastatic Urothelial Carcinoma: When Do We Need Further Histologic Staging? Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains. Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia. The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. New primary malignancy masquerading as metastatic prostate adenocarcinoma. Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I. Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission. Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. CD9 negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells. CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells. ALK1 as a novel therapeutic target for CD30⁺ T-anaplastic large cell lymphoma. The role of monoclonal antibodies in the treatment of lymphomas. Survey of the University of Florida Hematology/Oncology Fellows On Perceived Skills of Independent Management of Oncologic Pain, Chemotherapy-Related Nausea and Vomiting, and End-Of-Life Discussions Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion. Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells. Characterization of Cancer Stem Cell Properties of Cd24 and Cd26-Positive Human Malignant Mesothelioma Cells (Vol 419, Pg 529, 2012) CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients With Low-Affinity Cd16 Polymorphisms Advantages of Proton Therapy in the Management of Primary Mediastinal B-Cell Lymphoma (Pmbcl) Reducing the Dose To the Cardiac Chambers, Valves, and Vessels With Proton Therapy Compared With 3D-Crt and Imrt in Patients With Mediastinal Hodgkin Lymphoma Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines. Dipeptidyl peptidase in autoimmune pathophysiology. Combination therapy for renal cell cancer: what are possible options? A New Derivative of Roxithromycin Modulates Immunological Responses and Ameliorates Collagen-Induced Arthritis Inotuzumab ozogamicin as novel therapy in lymphomas. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects. Anti-Cd22 Immunoconjugate Inotuzumab Ozogamicin (Cmc-544) + Rituximab: Clinical Activity in Patients With Relapsed/Refractory Follicular Or `Aggressive' Lymphoma SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells. Anti-Cd22 Immunoconjugate Inotuzumab Ozogamicin (Cmc-544) + Rituximab: Clinical Activity Including Survival in Patients With Recurrent/Refractory Follicular Or `Aggressive' Lymphoma The role of CD26/dipeptidyl peptidase IV in cancer. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission. Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant cancer cells. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Roxithromycin specifically inhibits development of collagen induced arthritis and production of proinflammatory cytokines by human T cells and macrophages. Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Nedd9 protein, a Cas-L homologue, is upregulated after transient global ischemia in rats: possible involvement of Nedd9 in the differentiation of neurons after ischemia. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation. T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. SS-A/Ro52, an autoantigen involved in CD28-mediated IL-2 production. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review). CD26: a key molecule in immune regulation and autoimmune diseases. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. G1/S cell cycle arrest provoked in human T cells by antibody to CD26.
Log in to MyUFHealth
Primary tabs
Publications
BMC gastroenterology
2021
JAMA network open
2021
Biomarker research
2021
Cureus
2021
Leukemia & lymphoma
2021
Cell death & disease
2021
Cureus
2021
Cureus
2021
Cureus
2021
Case reports in surgery
2020
Cureus
2020
Pediatric transplantation
2020
Journal of investigative medicine high impact case reports
2020
Frontiers in oncology
2020
Lancet (London, England)
2020
Modern rheumatology
2019
Blood
2019
Cancer medicine
2019
PloS one
2019
Scientific reports
2019
mAbs
2019
The Journal of investigative dermatology
2019
Molecular and clinical oncology
2019
Biochemical and biophysical research communications
2018
British journal of haematology
2018
Frontiers in bioscience (Landmark edition)
2018
Experimental hematology & oncology
2017
Journal of drug assessment
2017
British journal of cancer
2017
Journal of dermatological science
2017
Critical reviews in immunology
2016
ACS chemical biology
2016
Case reports in oncological medicine
2016
Biochemical and biophysical research communications
2016
Leukemia & lymphoma
2016
Case reports in oncological medicine
2016
Biochemical and Biophysical Research Communications
2015
Journal of immunology (Baltimore, Md. : 1950)
2015
Leukemia & lymphoma
2015
Case reports in oncological medicine
2015
Modern rheumatology
2015
Case reports in oncological medicine
2015
Journal of clinical laboratory analysis
2015
Journal of immunology (Baltimore, Md. : 1950)
2015
British journal of cancer
2014
British journal of haematology
2014
International journal of radiation oncology, biology, physics
2014
Diagnostic pathology
2014
PloS one
2014
Biochemical and biophysical research communications
2014
Journal of the National Cancer Institute
2014
Expert opinion on biological therapy
2013
Journal of Clinical Oncology
2013
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013
British journal of haematology
2013
Diabetes research and clinical practice
2013
International Journal of Radiation Oncology Biology Physics
2013
British journal of haematology
2013
Journal of virology
2013
Immunology
2013
BMC cancer
2013
Case reports in hematology
2012
Clinical cancer research : an official journal of the American Association for Cancer Research
2012
Clinical cancer research : an official journal of the American Association for Cancer Research
2012
International journal of radiation oncology, biology, physics
2012
International journal of radiation oncology, biology, physics
2012
Biochemical and biophysical research communications
2012
Biochemical and Biophysical Research Communications
2012
Clinical cancer research : an official journal of the American Association for Cancer Research
2012
Blood
2012
British Journal of Haematology
2012
International Journal of Radiation Oncology Biology Physics
2011
BMC cancer
2011
Advances in clinical chemistry
2011
Oncology
2011
Arthritis and Rheumatism
2011
Expert opinion on biological therapy
2010
Biochemical and biophysical research communications
2010
Journal of ethnopharmacology
2010
Haematologica
2010
Biochemical and biophysical research communications
2009
Biochemical and biophysical research communications
2009
Biochemical and biophysical research communications
2009
British journal of cancer
2009
Biochemical and biophysical research communications
2009
Blood
2009
Frontiers in bioscience : a journal and virtual library
2008
Frontiers in bioscience : a journal and virtual library
2008
Trends in immunology
2008
Cancer research
2008
American journal of hematology
2008
Clinical & developmental immunology
2008
Biochemical and biophysical research communications
2007
British journal of haematology
2007
British journal of haematology
2007
Cancer research
2007
Clinical cancer research : an official journal of the American Association for Cancer Research
2007
Cancer investigation
2007
The Journal of biological chemistry
2007
Mini reviews in medicinal chemistry
2007
Modern rheumatology
2006
Clinical cancer research : an official journal of the American Association for Cancer Research
2006
Leukemia & lymphoma
2005
The Journal of rheumatology
2005
Cancer research
2005
Cancer
2005
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005
Stroke
2005
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005
Oncogene
2005
Cancer research
2005
Molecular and cellular biology
2005
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2004
Clinical cancer research : an official journal of the American Association for Cancer Research
2004
Clinical journal of oncology nursing
2004
Current drug targets. Immune, endocrine and metabolic disorders
2004
Proceedings of the National Academy of Sciences of the United States of America
2004
Blood
2004
British journal of haematology
2003
Journal of immunology (Baltimore, Md. : 1950)
2003
Oncology reports
2003
International journal of oncology
2003
Modern rheumatology
2003
Cellular immunology
2002
The Journal of rheumatology
2002
Immunology
2002
